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Abstract
Background: Malignant pleural mesothelioma (MPM) is a rare disease with poor prognosis in spite of significant
improvement in survival, due to new chemotherapy regimens. We describe here patients’ profiles and management
in daily practice in France.
Methods: Observational retrospective study. Data were collected from medical files. All patients with histologically
proven MPM diagnosed from January 2005 to December 2008 were included in the participating sites.
Results: Four hundred and six patients were included in 37 sites: mean age 68.9 ± 9.8 years, male predominance
(sex ratio 3.27), latency of the disease 45.7 years, epithelioïd type 83 %. Diagnosis was made using thoracoscopy in
80.8 % of patients. Radical surgery was performed in 6.2 % of cases. Chemotherapy was administered to 74.6 % of
patients. First line regimens consisted mainly of platinum + pemetrexed (91 %) or pemetrexed alone (7 %). Objective
response rate was 17.2 % and another 41.6 % of patients experienced disease stabilization. Half of these patients
underwent second line chemotherapy (platinium + pemetrexed 31.6 %, pemetrexed alone 24.6 %), resulting in a 6 %
response rate. Third-line chemotherapy (56 patients) yielded disease control in 5.4 % of cases.
Conclusions: The management of MPM in France is usually in accordance with guidelines. Response rates are somewhat
lower than those described in clinical trials.
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Background
Malignant pleural mesothelioma (MPM) is a rare aggressive
tumor. Since it is mainly associated with asbestos exposure,
its incidence varies among countries and population sub-
groups, depending on the degree of exposure.
The time between exposure and diagnosis of MPM
often exceeds several decades. It has been shown
recently that the risk continues to rise until 45 years fol-
lowing exposure [1]. The incidence of MPM is continu-
ously increasing in some contries as Australia and
United Kingdom [2–4] but remains very stable for over
5 years in U.S. and Japan. In France, the epidemiological
pattern is different since asbestos use has been strictly
controlled as early as 1978 and definitely forbidden in
1997. New cases are still diagnosed due to the long
latency of the disease, but apparently, the incidence peak
has been reached in 2000–2005 for men [5]. However, in
the meantime, the incidence is still increasing in women,
in whom professional exposure is often missing. The
number of MPM-related deaths is approximately 1100/
year in men and 300/year in women in France [5] while
the incidence ranges from less than 1/million for the
general population to 50–100/million for at-risk sub-
groups [5]. A national network has been created in 1998
(PNSM: Programme National de Surveillance des
Mésothéliomes) for epidemiological observation, clinical
research and organization of healthcare supply [6]. Apart
from the well-known occupational exposure, environ-
mental exposure to asbestos or other carcinogenic com-
pounds remains to be explained while they seem to
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account for more and more cases [4]. No oncogenic
driver has been identified and molecular pathways lead-
ing to MPM are also unclear, so that up to now, there is
no evidence for using specific targeted therapies in the
treatment of these tumors and most clinical trials
yielded negative outcomes [7]. Extrapleural pneumonec-
tomy preceded by neoadjuvant chemotherapy and
followed by hemithorax irradiation has been almost
abandoned in routine practice, since several clinical tri-
als have demonstrated low feasibility, absence of survival
benefits and unacceptable postoperative morbimortality
[8, 9]. Treatment of advanced diseases relies primarily
on chemotherapy with a combination of platinum and
pemetrexed until the results of ongoing clinical trials
provide information that may change our practice (asso-
ciation with bevacizumab,new targeted therapies or
immunotherapy).
The objective of our study was to describe the pa-
tients’ profiles and the management of MPM in France,
as regards diagnosis and treatment.
Methods
In this observational national multicenter study, we
retrospectively reviewed the medical files of patients di-
agnosed and treated in France. All the sites belonging to
the GFPC (French Group of Onco-Pneumology) were
invited to participate. Patients were included if they had
a histologically proven MPM diagnosed between January
2005 and December 2008, and if they had been managed
in the participating site. Patients who were treated for
recurrent mesothelioma during this period were ex-
cluded if the diagnosis had been made before January
2005. The following information was recorded: patients’
demographics, smoking status and medical history,
exposure to asbestos (assess by a specific questionnaire),
symptoms, diagnostic procedures, type of treatment
(surgery, radiation therapy and chemotherapy) and re-
sponse to treatment, as evaluated by local investigators.
Descriptive statistics were used, namely means, standard
deviations, medians and ranges for quantitative variables,
counts and percentages for categorical variables. No statis-
tic tests were performed. The date of last observation was
December 31, 2008. The protocol was approved by the
CHU Limoges ethics committee, on behalf of all partici-
pating centers, and the study complied with good clinical
practice and the Helsinki Declaration. All participants
signed informed consent.
Results
We included 406 patients diagnosed and managed at 37
sites (203 cases in 16 teaching hospitals, 183 in 18 gen-
eral hospitals, 14 in 2 cancer research centers and 6 in
one military hospital). Their main characteristics are
summarized in Table 1. Men accounted for 77 % of the
cohort; most frequent comorbidities were high blood
pressure (37.7 %) and cardiovascular diseases (17 %). A
majority of patients had respiratory symptoms at diagnosis
(93 %), mainly dyspnea and thoracic pain. A previous ex-
posure to asbestos was identified in 64 % of cases and the
mean time from exposure to diagnosis was 45.7 years.
Examinations performed for disease staging included
thoracic CT scan (98 %), abdomino-pelvic CT scan
(65 %), echocardiography (22 %), PET-scan (24 %) and
magnetic resonance imaging (10 %). Diagnosis was based
on surgical thoracoscopic/pleuroscopic biopsy in most
cases (Table 2). The epithelioïd type was the most fre-
quent (82.9 %) followed by sarcomatoid (10 %) and
mixed or biphasic (7.1 %) types.
Only 30 patients underwent curative surgery, namely
extra-pleural pneumonectomy and pleurectomy in 25
and 5 cases respectively. In addition, pleurodesis was
performed in 191 patients. Two hundred and sixty-eight
patients had prophylactic drain site radiation therapy
with a mean number of 5.2 ± 6.2 sessions and a mean
number of 6 ± 2.2 Gy per session.
First-line chemotherapy was administered to 303
(74.6 %) patients, among whom 162 (53.5 %) and 56
(18.5 %) had second- and third-line chemotherapy
Table 1 Main characteristics of patients (n = 406)
Age at diagnosis, years (mean + SD) 68.9 ± 9.8
Gender, male 76.6 %
Smoking status (n = 367)
Never smoker, n (%) 152 (42.4 %)
Current smoker, n (%) 36 (9.8 %)
Past smoker, n (%) 179 (48.8 %)
Pack-years, mean ± SD 28 ± 17.1
Medical history, n (%)
Cancer 40 (9.8 %)
Chronic obstructive pulmonary disease 17 (4.2 %)
Cardiovascular disorders 69 (17.0 %)
High blood pressure 153 (37.7 %)
Neurovascular disorders 15 (3.7 %)
Asbestosis 7 (1.1 %)
Diabetes mellitus 54 (13.0 %)
Symptomatic at diagnosis (n = 373), n (%)
Yes 347 (93.0 %)
Dyspnea 248 (71.5 %)
Thoracic pain 154 (44.4 %)
Other 158 (45.5 %)
Exposure to asbestos (n = 406), n (%) 259 (63.8 %)
Type of exposure (n = 259)
Professional 251 (96.9 %)
Environmental 8 (3.1 %)
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respectively (Fig. 1). Most frequently used chemotherapy
regimens were cisplatin – pemetrexed in first line, and
gemcitabine as single agent in 2nd and 3rd line (Fig. 2).
The mean (median) numbers of cycles were 4.7 ± 1.7
[6], 3.5 ± 1.9 [3] and 3.1 ± 2 [3] in first, second and third
lines respectively. The percentage of patients who
responded to or were stabilized by treatment decreased
over line, from 60.1 % in first line to 5.3 % in third line
chemotherapy (Table 3).
Discussion
We described here patients’ characteristics and manage-
ment of MPM in France. This patient cohort represent
only 10 % of all patients diagnosed and treated in
France; but it should be highlighted that all high volume
centers participated and the remaining patients are
treated individually throughout the country in centers
with very low volumes. Since MPM is a rare disease,
there are few such reports in the literature. A Turkish
series of 228 patients diagnosed and followed from 1993
to 2010 was published in 2012 [10]. Age at diagnosis
was 10 years younger in the Turkish cohort (59 years)
and sex ratio was only 1.4 in favor of men. The type of
exposure was probably different since most patients
were farmers and housewives, and lived in rural areas.
Diagnostic procedures were also different since blind
closed pleural needle biopsy was performed in more
than one half of patients and thoracoscopy in only 3 %.
In another Turkish cohort of 54 patients from a single
center, age was also younger (60.3 years for men), male
predominance was moderate (55.6 %) and epithelioïd
type accounted for only 50 % of the tumors [11]. These
findings suggest that the epidemiology of mesothelioma
is different in France and Eastern European countries,
where tumors are more frequent in women and occur at
younger ages, with a different distribution of histological
types. Indeed, it is well known that in Turkey, environ-
mental exposure is frequent due to opencast asbestos
mines, and genetic predisposition has been shown in
some regions [12].
Table 2 Diagnostic procedures (n = 406)
Blind closed pleural needle biopsy with local anesthesia 16 (3.9 %)
Medical thoracoscopic biopsy 11 (2.7 %)
Surgical thoracoscopic biopsy 317 (78.1 %)
Biopsy by thoracotomy 45 (11.1 %)
CT-scan guided blind closed pleural needle biopsy 16 (4 %)
Unknown 1 (0.2 %)
Fig. 1 Chemotherapy administration
Fig. 2 Chemotherapy regimens used in first, second and third line
(% of cycles)
Table 3 Clinical response
First line chemotherapy (n = 303)
Complete response 9 (3.0 %)
Partial response 43 (14.2 %)
Stable disease 126 (41.6 %)
Disease control (CR + PR + SD) 178 (58.8 %)
Progression 99 (32.7 %)
Non evaluable 26 (8.5 %)
Second line chemotherapy (n = 162)
Complete response 1 (0.6 %)
Partial response 9 (5.4 %)
Stable disease 31 (18.6 %)
Disease control (CR + PR + SD) 41 (24.6 %)
Progression 78 (46.7 %)
Non evaluable 48 (28.7 %)
Third line chemotherapy (n = 56)
Complete response 0
Partial response 1 (1.8 %)
Stable disease 2 (3.6 %)
Disease control (CR + PR + SD) 3 (5.4 %)
Progression 27 (48.2 %)
Non evaluable 26 (46.4 %)
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The latency in our cohort was 45.7 years, which is
consistent with other epidemiological studies [1, 3, 4]. It
has been shown that apart from intensity and duration
of exposure, the risk of MPM is inversely correlated with
the age at first exposure [13]. However, this information
has not been recorded in our patients’ files.
During the 2003–2007 5-year period, the pathological
branch of the PNSM network (a mandatory, national re-
view) analyzed 1348 pleural biopsies, among which 82 %
were malignant mesotheliomas [6]. In this large sample
of MPM, 80 % were epithelioïd, 6 % were sarcomatoid
and 11 % were biphasic. Although our study included
only 1/10th of the estimated total number of cases of
MPM diagnosed in France in the same period, the distri-
bution of histological types is very similar to ours and
these data suggest that our cohort is representative of
MPM in France.
Main guidelines in the diagnosis and management of
MPM are those issued by the European Respiratory
Society - European Society of Thoracic Surgeons (ERS-
ESTS) [14] and those issued by the European Society of
Medical Oncology (ESMO) [15]. The use of positron
emission tomography (PET) scanning is still under
debate because MPM tends to only grow locally and
metastases occur solely in patients with advanced dis-
ease but PET scanning can be used in the diagnostic
work-up when
PET-avid sites in the thoracic cavity need to be identi-
fied to obtain representative tissue. In this analysis, only
24 % of the patients had a Pet scan as initial procedure;
this can be explain by a limited access to this test in
France, particularly at the study period. From a diagnos-
tic perspective, thoracoscopy is recommended by ERS-
ESTS for the pathological diagnosis of MPM, using deep
and large biopsies while cytology and fine needle biop-
sies are considered insufficient. The ESMO also states
that histology is the gold standard, using pleuroscopy or
open pleural biopsy. In our series, almost all atients had
a MPM diagnosis based on histology, biopsies being
obtained by thoracoscopy and thoracotomy in the
majority of cases.
Few options are available for the treatment of MPM
and its prognosis remains very poor with a median over-
all survival below 12 months [16]. Extrapleural pneu-
monectomy does not offer survival benefits and it is
accompanied by high morbidity and mortality [9, 17].
Both ERS-ESTS and ESMO guidelines recommend that
extrapleural pleurectomy be performed only in a pallia-
tive setting to obtain symptoms control, and that radical
surgery be performed only in highly specialized centers,
as part of clinical trials, in a multimodal approach. In
our series, only 30 (7.4 %) patients underwent surgery
with curative intent. Of note, the results of the MARS
study [9] had not been published at this time.
Prophylactic irradiation of tracks, intending to avoid
tumor seeding after chest drain or pleural biopsy, is not
recommended due to discrepancies between the few
studies and to insufficient data [8–21]. Despite this rec-
ommendation, in our study, a large part of patients,
65.5 % received a prophylactic irradiation of tracks.
According to guidelines, when the decision is made to
administer chemotherapy, first line treatment should
consist of platinum associated with pemetrexed or ralti-
trexed [14, 22, 23]. This recommendation was followed
by the French sites in our study since 91 % of first-line
regimens consisted of platinum + pemetrexed.
In the initial study published by Vozelgang et al. in
2003, pemetrexed plus cisplatin was compared to cis-
platin alone in chemonaïve patients [22]. The combin-
ation with pemetrexed resulted in longer overall survival
(12.1 vs 9.3 months, p = 0.02), and increased response
rates (41.3 vs 16.7 %, p < 0.0001). In our cohort, only
17.5 % of patients responded to this first-line chemo-
therapy, while the median number of cycles [6] was
similar. According to the preliminary results of an Italian
cohort of patients (n = 322) receiving pemetrexed alone
(28 %) or associated with cisplatin or carboplatin, the
overall response rate was 28.5 % [24]. However, in the
phase II study published in 2006 by Ceresoli et al., only
18.6 % of patients treated with pemetrexed + carboplatin
(19/102) had an objective response, including 2 CR and
17 PR, while 65.7 % achieved disease control, which is
more consistent with our findings [25]. However, the re-
sponse rate observed in our retrospective cohort seems
low and has to be considered with caution. Indeed, in
our study, there was no centralized review of the re-
sponse to treatment and the follow-up of the patients
was not standardized.
Drugs to be used in second line are not well-defined:
guidelines suggest, with low levels of evidence, re chal-
lenge with the initial combination in case of response, or
vinorelbine, or inclusion in clinical trials [14, 15]. In our
series, the response rate was very low in the second-line
setting (6 %) and only 24.6 % of patients had disease
control. This result rate is consistent with that observed
in a US study (2 %) that retrospectively reviewed the
outcome of gemcitabine and/or vinorelbine chemother-
apy in pemetrexed pretreated patients [26]. However, in
this series of 60 patients, 46 % had stable disease, which
is much higher than in ours. In another trial, vinorelbine
single agent administered as second or further line
chemotherapy in pemetrexed pretreated patients yielded
a 15.2 % response rate and 33.9 % stable disease [27]. In
a Japanese study, gemcitabine + vinorelbine administered
as second line or beyond to pemetrexed pretreated
patients resulted in 18 % response rate and 82 % disease
control [28]. Retreatment with pemetrexed (alone or in
combination, second or further line) appears a valuable
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option with a 19 % response rate and 48 % disease con-
trol rate in an Italian study [29]. Response to rechallenge
appears to be correlated with response to first line
pemetrexed-based chemotherapy.
Due to the methodology of our study, several data are
missing because they are not systematically reported in
medical records in routine practice. We could not estab-
lish survival curves since we did not collect longitudinal
data. However, we could show that our patients are rep-
resentative of the French MPM patients, that recom-
mendations are appropriately followed with regards to
both diagnostic procedures and treatment, and that un-
fortunately, treatment outcomes in daily practice are not
as good as those reported in clinical trials. Actually, new
treatment options are urgently needed to improve pa-
tients’ prognosis. Targeted therapies yielded disappoint-
ing results up to now [7] and further results are eagerly
awaited, such as those of the MAPS study [30]. In the
recent ASCO congress, promising results from new and
original approaches such as arginine deprivation [31] or
vaccines [32] were reported. However, these data must
be considered very cautiously, until they are confirmed
in further studies.
Conclusion
We showed in this study that the management of MPM
in France is in line with European recommendations.
Yet, treatment outcomes remain disappointing, usually
lower in routine practice than in clinical trials. New
treatment options are urgently needed to improve the
prognosis of MPM.
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